SHORTEN-TB (Developing Lead Compounds to Shorten the duration of Tuberculosis Chemotherapy) will build upon the lessons learned from the HIT-TB program and from other recent advances in our understanding of the rate-determining lesions in dictating the treatment shortening potential of individual series as early as possible. We will progress advanced series from the HIT-TB program that are predicted to be associated with those characteristics that define agents with potential to shorten the duration of chemotherapy based on clinical evidence (oxazolidinones) or mechanistic novelty where the engaged targets are predicted to be essential in the context of human pathogenesis.


  • To identify new leads and drug candidates to shorten the duration of TB drug therapy for all TB patients.


Public-Sector Partners:
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI) 
National Institute of Allergy and Infectious Diseases (NIAID)

Private-Sector Partners:
Bill & Melinda Gates Foundation*

Academic Partners:
University of Cambridge
University of Cape Town
University of Dundee

*Provided financial or in-kind support for this program.

FNIH Contacts

Susan Wiener, Senior Project Manager,